Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE®) plus carboplatin followed by a continuation of mirvetuximab soravtansine monotherapy in patients with ≥50 % folate receptor...
Hence then, the article about abbvie showcases late breaking phase 2 data for mirvetuximab soravtansine gynx elahere in platinum sensitive ovarian cancer psoc at sgo 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 )
Also on site :
- ‘Saturday Night Live’ Opens With Donald Trump And Pete Hegseth Reveling In The Prospect Of Bombing Iran Again
- How much your local council is spending on SEND schools
- Artemis II astronauts receive hero’s welcome as they return to Houston after splashdown back on Earth